Literature DB >> 3707859

Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies.

G J Mufti, A Figes, T J Hamblin, D G Oscier, J A Copplestone.   

Abstract

The immunoglobulin levels and autoantibody profiles of 104 patients with primary myelodysplastic syndromes (MDS), classified according to the FAB criteria, were analysed. Eight patients, four with coexistent non-Hodgkin's lymphomas, three with chronic lymphocytic leukaemia and one with a lymphoplasmacytoma, were excluded from the final analysis of immunoglobulin levels. Serum protein electrophoresis and immunoelectrophoresis revealed the presence of monoclonal gammopathy in 12 patients (12.5%). Of the remaining 84 patients, a polyclonal rise in serum immunoglobulins was present in 27 (32%) while a further 16 (19%) had low immunoglobulin levels. The direct antiglobulin test was positive in eight out of 98 patients tested (8.1%), and organ and non-organ specific autoantibodies were present in 15 out of 67 patients tested (22.3%). Two patients had associated pernicious anaemia (PA), two hypothyroidism, and one PA with hypothyroidism. Three patients had sero-negative rheumatoid arthritis. These results demonstrate that there is a high incidence of immunological abnormalities in MDS.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3707859     DOI: 10.1111/j.1365-2141.1986.tb07504.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

1.  Coincidence of primary myelodysplastic syndrome and non-Hodgkin lymphoma.

Authors:  R Schulze; G Schlimok; D Renner
Journal:  Clin Investig       Date:  1992-12

2.  Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient.

Authors:  Caterina Stefanizzi; Massimo Breccia; Michelina Santopietro; Serelina Coluzzi; Laura Cannella; Gabriella Girelli; Giuliana Alimena
Journal:  Int J Hematol       Date:  2009-05-26       Impact factor: 2.490

3.  Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes.

Authors:  R J Sokol; S Hewitt; D J Booker
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

4.  Immunological abnormalities in myelodysplastic syndrome.

Authors:  B Seitanides; A Antonopoulou; A Karabelis
Journal:  J Clin Pathol       Date:  1988-08       Impact factor: 3.411

5.  Sweet's syndrome and myelodysplasia.

Authors:  D K Knight; D M Layton; G J Mufti; H Williams
Journal:  Blut       Date:  1988-01

6.  A case of erythema nodosum and serositis associated with myelodysplastic syndrome.

Authors:  Jung-Hye Choi; Myung-Ju Ahn; Yong-Wook Park; Ho-Suk Oh; Young-Yeul Lee; In-Soon Kim
Journal:  Korean J Intern Med       Date:  2005-06       Impact factor: 2.884

7.  Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A.

Authors:  Toshiki Yamada; Hisashi Tsurumi; Senji Kasahara; Takeshi Hara; Michio Sawada; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-10       Impact factor: 4.553

8.  Myelodysplastic syndrome associated with relapsing polychondritis: unusual transformation from refractory anemia to chronic myelomonocytic leukemia.

Authors:  T Shirota; O Hayashi; H Uchida; N Tonozuka; N Sakai; H Itoh
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

Review 9.  Oxidative stress and the myelodysplastic syndromes.

Authors:  Morag J Farquhar; David T Bowen
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

Review 10.  Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia.

Authors:  D M Layton; G J Mufti
Journal:  Blut       Date:  1986-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.